Patricia Inácio, PhD, science writer —

Adults using Kalydeco (ivacaftor) or Trikafta (ivacaftor/tezacaftor/elexacaftor) to treat their cystic fibrosis (CF) showed gains in lung function and nutritional status, according to a real-world, observational study in Australia. In contrast, no significant improvements in lung function were seen in adults or children with CF using Orkambi (ivacaftor/lumacaftor)…

The annual number of new cases of nontuberculous mycobacteria (NTM) lung infections is increasing in the U.S. among people with cystic fibrosis, a study finds. Between 2010 and 2019, the incidence, or new cases, of infections increased by 3.5% a year, with the highest number seen in the South. NTN…

Two new Strategic Research Centres (SRC), each leading a multiyear study into research priorities identified by cystic fibrosis (CF) patients, will open the U.K. in September. The work, which bring together scientists and specialists from different fields, is supported by £1.4 million — around $1.8 million — in funding…

A new adrulipase formulation for people with cystic fibrosis (CF), designed as a treatment for exocrine pancreatic insufficiency or EPI — when the small intestine is unable to fully digest food due to problems with digestive enzymes from the pancreas — was deemed safe and well tolerated in a…

Children with cystic fibrosis (CF) who have normal pancreas function — called pancreatic sufficiency (PS) — are at higher risk of being overweight and obese than those with pancreatic insufficiency (PI), according to a single-center study in Greece. According to its researchers, findings support a reevaluation of “the recommendation…

Changes in two human voice parameters may help identify poor control of blood sugar levels in people with cystic fibrosis (CF) who have CF-related diabetes (CFRD), a pilot study reported. Lower measures on these parameters, known as fundamental frequency variation and noise-to-harmonic ratio, were linked with higher glucose,…

Children and adolescents with cystic fibrosis (CF) commonly have procedural anxiety — a sudden and excessive fear of a medical procedure leading to acute stress or avoidance — that’s associated with treatment resistance, according to a recent study. Parents and caregivers reported three out of four children view at…

The Phase 2 SPAN clinical trial of a new formulation of adrulipase in treating exocrine pancreatic insufficiency (EPI) in adults with cystic fibrosis (CF) has reached more than half of its target enrollment. Enrollment is ongoing at three U.S. sites, one each in Florida, Illinois, and Nevada. CF…

Monitoring the concentration of antibiotics in the blood — a clinical practice called therapeutic drug monitoring — was linked to fewer pulmonary exacerbations and less lung function decline in people with cystic fibrosis (CF), a small study reports. The study, “Therapeutic drug monitoring in cystic fibrosis…

Treatment with Orkambi (lumacaftor/ivacaftor) for six months lessened airway inflammation and enhanced airway bacterial diversity in people with cystic fibrosis (CF), but only when administered before patients were chronically infected with the bacterium Pseudomonas aeruginosa, a study has found. The findings suggest that “CFTR modulators [such as Orkambi] should…